Zydus lifesciences ltd., Pharmaceutical company

Zydus Lifesciences on Monday said it has received approval from the Drug Controller General of India (DCGI) for a new drug application, Oxemia (Desidustat), a first-of-its-kind oral treatment in India for anemia associated with chronic kidney disease.Oxemia is an oral, small molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor.The clinical development programme of Oxemia (Desidustat) was one of the largest trials of its kind in India for anemia in chronic kidney disease (CKD) patients, conducted in over 1200 subjects.Desidustat provides CKD patients with an oral convenient therapeutic option for the treatment of anemia."Our life changing discoveries are guided by the need to help patients lead a better life and empower them with therapies that enable them to live healthier and more fulfilled lives," Pankaj R Patel, Chairman, Zydus Lifesciences Ltd, said in a statement."There was a potential for an oral, safer alternative to currently available injectable erythropoietin- stimulating agents (ESAs). After more than a decade of research and development into the science of HIF-PH inhibitors, results have demonstrated that Oxemia (Desidustat) addresses this unmet need and additionally reduces hepcidin, inflammation and enables better iron mobilisation," Patel said.Chronic kidney disease (CKD) is a serious progressive medical condition characterised by a gradual loss of kidney function, usually accompanied by other comorbidities including anemia, cardiovascular diseases (hypertension, heart failure and stroke), diabetes mellitus, eventually leading to kidney failure.( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Home

City

Latest News

Cricket

LT Premium

National

International

Maharashtra

Opinions

Chhatrapati Sambhajinagar

Nagpur

Entertainment

Photos

Business

Technology

Sports

Lifestyle

Social Viral

Lokmat Games

Health

Pahalgam Terror Attack

Tahawwur Rana

IPL 2025

CM Devendra Fadnavis

Mumbai Local

Weather Update

Zydus Lifesciences Ltd.FOLLOW

Zydus lifesciences ltd., Latest News

National :DCGI grants EUA to ZycovD COVID vaccine for two-dose regimen for children above 12

The Drugs Controller General of India (DCGI) on Tuesday granted Emergency Use Authorisation (EUA) to Zydus Cadila vaccine (ZycovD) for COVID-19 as a two-dose vaccine for children above the age of 12 years, said Zydus Lifesciences Ltd., the pharmaceut ...

National :Zydus receives final approval from USFDA to market Colestipol Hydrochloride tablets

Zydus Lifesciences Ltd. has received final approval from the United States Food and Drug Administration (USFDA) to market Colestipol Hydrochloride Tablets in the strength of 1mg (US RLD: Colestid), said the pharmaceutical company on Monday. ...

Business :Zydus Lifesciences gets DCGI approval for Oxemia drug

Zydus Lifesciences on Monday said it has received approval from the Drug Controller General of India (DCGI) for a new drug application, Oxemia (Desidustat), a first-of-its-kind oral treatment in India for anemia associated with chronic kidney disease ...